COBAS AMPLIPREP / COBAS TAQMAN 48 ANALYZER

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05 report with the FDA on 2010-10-04 for COBAS AMPLIPREP / COBAS TAQMAN 48 ANALYZER manufactured by Roche Diagnsotics, Ltd..

Event Text Entries

[1432066] A customer in the (b)(6) filed a complaint stating that the cobas ampliprep / cobas taqman 48 hiv-1 test ((b)(4) batch k11455) using amplilink software v 3. 2 generated a result of (b)(6) cp/ml with a target ct value of about (b)(6). The original result was reported to the patient's physician; however, the clinician did not believe the test result as (b)(6). There was no adjustment in the patient's therapy; however, the patient was contacted and a new specimen was collected. Retest results from the new specimen collection generated a (b)(6). However, the patient was identified as being pregnant, and therefore, if this (b)(6) result was reported close to the patient's delivery date, there could have been patient management implications. (b)(6).
Patient Sequence No: 1, Text Type: D, B5


[8785145] At the time this complaint was investigated, a review of the data showed the (b)(6) result was due to a noisy baseline. The elth algorithm was unable to normalize this curve, which resulted in a (b)(6). During the normalization, the algorithm excluded several baseline points due to the noise criterion of the elth algorithm. The few remaining points were not sufficient to reflect the entire baseline. The issue is still under investigation. The issue is considered to be a rare occurence. As stated in the package insert, this test is intended for use in conjunction with overall clinical presentation and other laboratory markers of disease progress to monitor the effectiveness of antiretroviral and antiviral therapy. In that regard, to the extent that observed sudden titer shifts are inconsistent with previous test results and overall clinical presentation, they should not result in changes to established therapy regimes. We recognize that this medical device report is being filed beyond the 30-day reporting timeframe as outlined within 21 cfr 803. 50. During a review of our mdr process, we determined that not all events that occurred ex-us were being assessed for mdr reportability within the united states. As a result, all potentially critical complaints (us and ex-us) filed going back to 01-jan-2008 were reassessed to determine if any of those cases represented a mdr reportable event. During the retrospective review, this event was identified as being mdr reportable. We are taking appropriate internal corrective actions to prevent recurrence of late filings.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number2243471-2010-00017
MDR Report Key1851150
Report Source05
Date Received2010-10-04
Date of Report2010-03-26
Date of Event2009-07-05
Date Mfgr Received2009-02-17
Date Added to Maude2012-01-06
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional0
Initial Report to FDA0
Report to FDA0
Event Location0
Manufacturer ContactVINCENT STAGNITTO
Manufacturer Street1080 US HWY 202
Manufacturer CityBRANCHBURG NJ 088763733
Manufacturer CountryUS
Manufacturer Postal088763733
Manufacturer Phone9082537569
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameCOBAS AMPLIPREP / COBAS TAQMAN 48 ANALYZER
Generic NameANALYZER, CHEMISTRY, MICRO, FOR CLINICAL USE
Product CodeJJF
Date Received2010-10-04
ID NumberAMPLILINK SOFTWARE V 3.2
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerROCHE DIAGNSOTICS, LTD.
Manufacturer AddressFORRENSTRASSE ROTKREUZ, ZUG 6343 SZ 6343


Patients

Patient NumberTreatmentOutcomeDate
10 2010-10-04

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.